DMRA
HealthcareDamora Therapeutics, Inc. · Biotechnology · $2B
What is Damora Therapeutics, Inc.?
Galecto, Inc. is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting cancer and fibrotic diseases. Headquartered in Boston, MA, the company is working to address serious unmet medical needs through novel biological mechanisms.
Galecto develops small molecule inhibitors designed to interfere with biological processes central to cancer progression and fibrosis. Its lead programs target galectin-3 and LOXL2, two proteins implicated in tumor growth and tissue scarring. As a clinical-stage company, Galecto does not yet generate product revenue — its business model centers on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization.
Galecto was founded in 2011 and is headquartered in Boston, MA.
- Small molecule galectin-3 inhibitors
- LOXL2 inhibitor programs
- Oncology pipeline candidates
- Fibrotic disease therapeutics
Is DMRA a Good Stock to Buy?
UQS Score rates DMRA as Poor overall, reflecting the early-stage nature and current financial profile of the business.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's near-term financial stability is better than its overall score might imply. This is not uncommon for clinical-stage biotechs that carry cash reserves to fund ongoing trials.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue company that has yet to establish a durable competitive position or demonstrated earnings power. Valuation is rated Elevated, meaning the current market price may not offer a margin of safety.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DMRA pay dividends?
No — Damora Therapeutics, Inc. does not currently pay a dividend.
Galecto does not pay a dividend, which is typical for clinical-stage biotechnology companies. Available capital is directed toward funding research, clinical trials, and pipeline development rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does DMRA report earnings?
Galecto reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly results primarily reflect operating expenses tied to research and development activity rather than product sales. Cash runway and trial progress are typically the key metrics investors monitor each reporting period.
For the most recent quarter's results, visit Galecto's investor relations page directly.
DMRA Price History
-72.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Damora Therapeutics, Inc.?
Based on Damora Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DMRA Long-term Outlook
Galecto's fundamental outlook is shaped by its clinical pipeline rather than near-term revenue generation. The Weak Growth pillar reflects the absence of commercial products, while the Good Risk rating suggests the company maintains enough financial stability to continue operations in the near term. Progress in galectin-3 and LOXL2 programs will be the primary catalyst for any meaningful change in the company's trajectory.
Growth drivers
- Advancement of galectin-3 inhibitor candidates through clinical milestones
- Potential partnerships or licensing agreements for pipeline assets
- Growing clinical and scientific interest in fibrosis and oncology targets
Key risks
- Clinical trial failure or delays could significantly impair pipeline value
- Elevated Valuation rating suggests limited downside cushion at current prices
- Ongoing cash consumption without product revenue creates dilution risk
DMRA vs Peers
Galecto operates in a competitive clinical-stage biotech landscape alongside other development-stage companies pursuing novel therapeutic mechanisms.
Cullinan focuses on a portfolio approach to oncology drug development, spreading pipeline risk across multiple targeted cancer programs.
Atai pursues a platform model in mental health therapeutics, differentiating itself through a decentralized, multi-asset development structure.
High Tide operates in cannabis retail and data analytics, representing a distinct business model from Galecto's pure clinical-stage biotech focus.
Frequently Asked Questions
What does Galecto do?
Galecto is a clinical-stage biotechnology company developing small molecule drugs that target biological processes driving cancer and fibrotic diseases. Its primary programs focus on inhibiting galectin-3 and LOXL2, two proteins involved in tumor growth and tissue scarring. The company has not yet commercialized any products.
Does DMRA pay dividends?
No, Galecto does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests available capital into research and clinical development. Dividends are not typical for companies at this stage of the biotech lifecycle.
When does DMRA report earnings?
Galecto reports on a quarterly cadence, as required for US-listed public companies. For exact dates and the most recent results, check the investor relations section of Galecto's official website.
Is DMRA a good stock to buy?
UQS Score rates DMRA as Poor overall. The Quality, Moat, and Growth pillars are all Weak, and Valuation is Elevated. The relative strength lies in the Risk pillar. Investors should weigh these factors carefully against their own risk tolerance and investment goals.
Is DMRA overvalued?
The UQS Valuation pillar for DMRA is rated Elevated, suggesting the current market price may not offer a significant margin of safety relative to the company's fundamentals. This is a common dynamic for clinical-stage biotechs where market pricing reflects speculative pipeline potential.
How does DMRA compare to its competitors?
Galecto competes in the clinical-stage biotech space alongside companies like Cullinan Therapeutics and Atai Beckley. Each pursues different therapeutic areas and development strategies. Galecto's differentiation lies in its specific focus on galectin-3 and LOXL2 biology in oncology and fibrosis.
What is DMRA's market cap bracket?
DMRA is classified as a small-cap stock. This places it in a category that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, which is consistent with its clinical-stage development profile.
Who founded Galecto?
Galecto was founded in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye — scientists and entrepreneurs with backgrounds in galectin biology and drug discovery.
Is DMRA a long-term quality investment?
As a long-term quality indicator, UQS Score rates DMRA as Poor. The Weak scores across Quality, Moat, and Growth pillars reflect the absence of established revenue, competitive advantages, or demonstrated earnings power — all factors that typically underpin long-term investment quality.
What is the main competitive advantage of Galecto?
Galecto's potential edge lies in its specialized focus on galectin-3 and LOXL2 inhibition — a relatively narrow scientific niche. However, the UQS Moat pillar is rated Weak, indicating that a durable competitive advantage has not yet been established at this stage of development.
Unlock Full DMRA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for DMRA
- ✓Access underlying financial metrics and trend data
- ✓Compare DMRA against peers on Quality, Growth, Moat, Risk, and Valuation
- ✓Screen clinical-stage biotechs by pillar strength across the sector
- ✓Get the full analyst view available exclusively to Pro members
Pro Analysis
DMRA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jun 13, 2026 | 9.4 | 0.0 | 5.0 | 0.0 | 54.0 | 0.0 | 0.0 |
| Jun 5, 2026 | 9.4 | 0.0 | 5.0 | 0.0 | 54.4 | 0.0 | -15.0 |
| May 22, 2026 | 24.4 | 0.0 | 5.0 | 0.0 | 54.4 | 100.0 | +13.6 |
| Apr 19, 2026 | 10.8 | 0.1 | 5.0 | 0.0 | 63.8 | 0.0 | -11.3 |
| Apr 12, 2026 | 22.1 | 0.1 | 50.0 | 0.0 | 63.8 | 0.0 | — |
DMRA — Pillar Breakdown
Quality
— 0.0/100 (25%)Damora Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Damora Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 54.0/100 (15%)Damora Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Damora Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 5/100 (25%)Damora Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DMRA.
Score Composition
Financial Data
More Stock Analysis
How is the DMRA UQS Score Calculated?
The UQS (Unified Quality Score) for Damora Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Damora Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Damora Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.